BAM
BPMC

Belpointe Asset Management’s Blueprint Medicines BPMC Stock Holding History

Belpointe Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-147
Closed -$6.61K – 928
2023
Q1 		$6.61K Buy
147
+61
+71% +$2.75K ﹤0.01% 2903
2022
Q4 		$3.77K Buy
+86
New +$4.12K ﹤0.01% 3029

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Belpointe Asset Management's BPMC Position: Q2 2023 in Review

Belpointe Asset Management sold out of Blueprint Medicines (BPMC) in Q2 2023, closing a stake of 147 shares — an estimated $6.61K sold.

Belpointe Asset Management first reported a position in BPMC in Q4 2022 and held it in 2 quarters. The position peaked at $6.61K in Q1 2023. 222 funds tracked by Wall St. Rank hold BPMC as of Q2 2023.

  • Belpointe Asset Management reported no remaining Blueprint Medicines position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 147 Blueprint Medicines shares in Q2 2023, an estimated $6.61K.
  • Belpointe Asset Management first reported a position in Blueprint Medicines in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Blueprint Medicines position peaked at $6.61K in Q1 2023.
  • 222 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.